iTeos Therapeutics, Inc. - ITOS STOCK NEWS

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the virtual 10^th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. Michel Detheux, PhD, President and CEO, will lead a fireside chat at 3:00 p.m. ET. The live webcast will be accessible on the company’s website, with an archived replay available for 30 days. iTeos is focused on developing innovative immuno-oncology therapeutics, including inupadenant and EOS-448, targeting critical pathways in the tumor microenvironment.

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Michel Detheux, will present a company overview at the 39th Annual J.P. Morgan Conference on January 12, 2021, at 9:10 a.m. ET. The presentation can be viewed live on their website, with an archived version available for 30 days. iTeos is focused on developing innovative immuno-oncology therapeutics, including two clinical-stage programs: EOS-850 and EOS-448, targeting specific immuno-oncology pathways to enhance cancer therapy.

iTeos Therapeutics (Nasdaq: ITOS) announced participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The fireside chat will be available on-demand for registered attendees. iTeos specializes in developing advanced immuno-oncology therapeutics, focusing on two clinical-stage programs: EOS-850, an adenosine A2a receptor antagonist, and EOS-448, targeting TIGIT. Both candidates are currently undergoing Phase 1/2a clinical trials for advanced solid tumors. For more details, visit their investor website.

iTeos Therapeutics (NASDAQ: ITOS) reported its Q3 2020 financial results, highlighting strong progress in clinical development for its lead candidates, EOS-850 and EOS-448, both in Phase 1/2a trials. Despite challenges from COVID-19 affecting patient enrollment, data readouts for EOS-850 and EOS-448 are on track for 1H 2021. The company's cash position increased to $340 million, enabling ongoing operations. R&D expenses rose to $8.7 million, driven by clinical activities. iTeos aims to nominate a new drug candidate by the end of 2021, supporting its growth in immuno-oncology therapeutics.

iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced the appointment of Matthew Roden, Ph.D., as a new member of its Board of Directors, replacing Ansbert Gadicke, M.D. Dr. Roden, a Partner at MPM Capital, brings extensive leadership experience from both pharmaceutical and financial sectors, which is expected to enhance the company's strategic direction. His past roles include Senior Vice President at Bristol Myers Squibb, where he led over 100 business development transactions valued at over $125 billion. The company focuses on developing innovative immuno-oncology therapeutics.

iTeos Therapeutics (Nasdaq: ITOS) announced its participation in upcoming virtual investor conferences this November. Key events include:

• Credit Suisse 29th Annual Virtual Healthcare Conference
  Date: November 12, 2020, at 12:30 p.m. ET
• Jefferies Global Healthcare Conference
  Date: November 17-19, 2020
• SVB Leerink Oncology 1x1 Day
  Date: November 19, 2020

A live audio webcast of the Credit Suisse presentation will be available for 30 days. iTeos develops innovative immuno-oncology therapeutics, including EOS-850 and EOS-448, targeting advanced solid tumors.

iTeos Therapeutics (Nasdaq: ITOS) announced participation in two virtual investor conferences in September 2020. The Citi’s 15th Annual BioPharma Virtual Conference will take place from September 9-10, and the H.C. Wainwright 22nd Annual Global Investment Conference is scheduled for September 15 at 5:00 p.m. ET. A live audio webcast of the H.C. Wainwright presentation will be accessible on iTeos’ investor website, with a replay available for 30 days post-event. iTeos is focused on developing innovative immuno-oncology therapeutics to enhance treatment benefits for patients.

iTeos Therapeutics, a clinical-stage biopharmaceutical company, reported a successful IPO in July 2020, raising $229.7 million. As of June 30, 2020, the company had a strong cash position of $136.9 million, supporting ongoing clinical trials for its lead products, EOS-850 and EOS-448. Initial data from EOS-850's clinical trial showed promising results, with no dose-limiting toxicities and instances of clinical benefits. The company anticipates a data-rich 2021, aiming to leverage its expertise in immuno-oncology to enhance patient outcomes.

iTeos Therapeutics (Nasdaq: ITOS) has announced the pricing of its initial public offering (IPO) of 10,586,316 shares at $19.00 each, expected to raise approximately $201.1 million before expenses. Trading is set to commence on July 24, 2020. The IPO proceeds will support the company’s advancement in immuno-oncology therapeutics. The offering is anticipated to close on July 28, 2020, pending customary conditions. Underwriters have a 30-day option to purchase an additional 1,587,947 shares at the offering price.